Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

PHASE2UnknownINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

February 21, 2017

Primary Completion Date

January 1, 2022

Study Completion Date

August 19, 2022

Conditions
Circulating Tumor CellMetastatic Prostate Cancer
Interventions
DRUG

Cabazitaxel

25mg/m2 q3w

OTHER

Antihistamine

As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)

OTHER

Corticosteroid

As intravenous premedication (dexamethasone 8 mg or equivalent)

OTHER

H2 antagonist

As intravenous premedication (ranitidine or equivalent)

OTHER

Antiemetic

Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary

Trial Locations (9)

Unknown

Reinier de Graaf Groep, Delft

Admiraal de Ruyter Ziekenhuis, Flushing

Groene Hart Ziekenhuis, Gouda

Canisius Wilhelmina Ziekenhuis, Nijmegen

Erasmus MC, Rotterdam

Franciscus Gasthuis en Vlietland, Rotterdam

Maasstad Ziekenhuis, Rotterdam

Medisch Centrum Haaglanden, The Hague

Tweesteden Ziekenhuid, Tilburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Erasmus Medical Center

OTHER